IL141126A0 - Herpes virus vectors for dendritic cells - Google Patents

Herpes virus vectors for dendritic cells

Info

Publication number
IL141126A0
IL141126A0 IL14112699A IL14112699A IL141126A0 IL 141126 A0 IL141126 A0 IL 141126A0 IL 14112699 A IL14112699 A IL 14112699A IL 14112699 A IL14112699 A IL 14112699A IL 141126 A0 IL141126 A0 IL 141126A0
Authority
IL
Israel
Prior art keywords
herpes virus
dendritic cells
virus vectors
cell
virus
Prior art date
Application number
IL14112699A
Other languages
English (en)
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of IL141126A0 publication Critical patent/IL141126A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14112699A 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells IL141126A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
PCT/GB1999/002529 WO2000008191A2 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Publications (1)

Publication Number Publication Date
IL141126A0 true IL141126A0 (en) 2002-02-10

Family

ID=10836553

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14112699A IL141126A0 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Country Status (17)

Country Link
US (2) US6641817B1 (enExample)
EP (1) EP1100942B1 (enExample)
JP (1) JP4430824B2 (enExample)
KR (1) KR100635246B1 (enExample)
CN (1) CN1384884B (enExample)
AT (1) ATE374829T1 (enExample)
AU (1) AU765105B2 (enExample)
BR (1) BR9912653A (enExample)
CA (1) CA2337494C (enExample)
CY (1) CY1107844T1 (enExample)
DE (1) DE69937239T2 (enExample)
DK (1) DK1100942T3 (enExample)
ES (1) ES2294848T3 (enExample)
GB (2) GB9816781D0 (enExample)
IL (1) IL141126A0 (enExample)
PT (1) PT1100942E (enExample)
WO (1) WO2000008191A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
ES2254359T3 (es) 2000-01-21 2006-06-16 Biovex Limited Cepa viral para el tratamiento oncolitico de canceres.
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
JP2004529158A (ja) * 2001-05-02 2004-09-24 ラモツト・アツト・テル−アビブ・ユニバーシテイ・リミテツド 混成殺腫瘍ヘルペスウイルスベクター
EP1387694A2 (en) * 2001-05-09 2004-02-11 M'S Science Corporation Composition and method for treating cancer using herpes virus
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) * 2007-04-09 2009-01-14 인제대학교 산학협력단 이종 유전자 발현을 위한 숙주균 및 그의 이용방법
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
EP2408904B1 (en) 2009-03-20 2017-10-18 Mesoblast, Inc. Production of reprogrammed pluripotent cells
WO2011091272A1 (en) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
EP3134546A4 (en) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CN113230384A (zh) 2014-10-09 2021-08-10 丹娜法伯癌症研究院 用于治疗免疫失调的多次-可变il-2剂量方案
EP3265825A4 (en) 2015-03-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US12194080B2 (en) 2015-10-29 2025-01-14 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
AU2017238054B2 (en) 2016-03-21 2023-10-19 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
ES3033182T3 (en) 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
JP7245260B2 (ja) * 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｅｈｖ挿入部位ｕｌ４３
EP3773658A4 (en) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. KIR3DL3 AS HLA2 RECEPTOR, ANTI-HHLA2 ANTIBODY AND ITS USES
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US20230075965A1 (en) 2020-01-24 2023-03-09 Constantine S. Mitsiades Uses of biomarkers for improving immunotherapy
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
US20250381241A1 (en) 2021-11-29 2025-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
EP4479080A1 (en) 2022-02-16 2024-12-25 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228008T1 (de) * 1992-07-31 2002-12-15 Harvard College Herpesvirus impfstoffe
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation

Also Published As

Publication number Publication date
CN1384884B (zh) 2010-12-08
WO2000008191A3 (en) 2000-06-08
AU765105B2 (en) 2003-09-11
CY1107844T1 (el) 2013-06-19
JP4430824B2 (ja) 2010-03-10
US20050249707A1 (en) 2005-11-10
DE69937239D1 (de) 2007-11-15
GB2361921B (en) 2003-12-17
HK1037925A1 (en) 2002-02-22
KR20010072162A (ko) 2001-07-31
GB2361921A (en) 2001-11-07
DK1100942T3 (da) 2008-02-04
AU5182299A (en) 2000-02-28
ES2294848T3 (es) 2008-04-01
GB9816781D0 (en) 1998-09-30
GB0104400D0 (en) 2001-04-11
CA2337494C (en) 2009-06-23
EP1100942B1 (en) 2007-10-03
WO2000008191A2 (en) 2000-02-17
US6641817B1 (en) 2003-11-04
CN1384884A (zh) 2002-12-11
KR100635246B1 (ko) 2006-10-19
CA2337494A1 (en) 2000-02-17
EP1100942A2 (en) 2001-05-23
DE69937239T2 (de) 2008-07-24
ATE374829T1 (de) 2007-10-15
JP2003502008A (ja) 2003-01-21
PT1100942E (pt) 2007-12-06
BR9912653A (pt) 2001-05-02

Similar Documents

Publication Publication Date Title
GB2361921B (en) Herpes virus vectors for dendritic cells
ATE224442T1 (de) Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
PT1573465E (pt) Método e sistema para detecção heurística de infecções por vírus no código executável
HU9502949D0 (en) Polipeptides, polinucleotides, vectors and host cells, and vaccines against hepatitis virus infection, diagnostics, immunoassay and culturing methods
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
EP1192948A3 (en) Use of HSV mutant in the treatment of cancer
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
SE9604581D0 (sv) An agent against cancer and virus infections
IL102915A0 (en) Soluble low density lipoprotein receptor and its preparation
GB2376687A (en) Herpes viruses for immune modulation
GR3015437T3 (en) Non-a non-b sequences.
黄念宁 et al. 1-Soliton of the 1D magnetic system with an easy plane
WO1999013064A3 (en) Viral infection of cells using viral vectors
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
Jeong et al. Site symmetry of Er sup 3 sup+ in In sub 0 sub. sub 5 Ga sub 0 sub. sub 5 P
Usenko Irradiation of semi-limited inhomogeneous plasma; Vipromyinyuvannya napyivobmezhennoyi neodnoryidnoyi plazmi
AU4728299A (en) Antiproliferative and antiviral proteins and peptides
Burgos Jr We Forum, vol xviii No. 51-Apr. 17-23, 1995
Ranieri US Private Investment In 1990
MX9709514A (es) Viruses de fowlpox recombinantes y usos de los mismos.
DE59410140D1 (de) Rinderovarzellinie (FROv) zur Virusvermehrung
MX9606248A (es) Composiciones de polimero de propileno, metodos para las mismas, y articulos a partir de las mismas.
IT1295532B1 (it) Cassaforte antisfondamento senza aperture, non dotata di fonti energetiche per l'apertura elettromeccanica inserita nell'antina e,
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired